Aviragen Therapeutics (AVIR) Misses Q1 EPS by 1c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Boeing secures $3B revolving credit facility, amends existing agreements
• Hyatt Hotels (H) files mixed shelf